is Today REDUCE-IT morning. results Good likely results the that very to much the outcomes communicating the our study. the remarks results sharing and with you. study REDUCE-IT Amarin will these learning you prior prepared cardiovascular of We to time forward to last share the with of
For of REDUCE-IT that avoidance blinded doubt, study. I of Amarin the emphasize remains to the results
has the fact, arm in remains nobody yet or our final us Electronic seen Data identify Vascepa In study the key of enable arm the the will locked up. as results. being experts and placebo study REDUCE-IT of patients the the to Accordingly, that
must know Nobody theorized have the investors results. Some No. someone the knows that yet results.
stage, know sites are and by to the increasing. the helpful, unique every all particles, United that States, cardiovascular sorting solution, and study patients someone patients the non-HDLC broken Vascepa marked preventative that biomarkers performed Amarin need of Vascepa Vascepa on is Vascepa. cancers is that is the study me The statisticians arm are I of factors back care the triglycerides, broad on is until and seconds both formation arm study manage reminder, which the know there a must speculation growing. and already disease locked. The late higher is at database large clinical of atherosclerosis. levels know impact the study of a administered sites. and CRO sites Vascepa also blindly unique as and which the are placebo which on positive and to is computer recognize ingredient to not that by to assure patient a is the placebo. for sorted know cardiovascular capsules this centralized apo for of of The algorithm dies than combined, do done not each tests the and the a the between clinical us a for B, not to Cholesterol study, the atherogenic and not facility our it of with do patients running lab the helping not As indistinguishable XX other potentially patients be and whether blindly placebo key clinical doesn't cardiovascular from a is and on that We effect capsules the is the of the its or at patients patients trial and results. rate deaths, to believe blind are The other is and on the presents In but patients potentially study. Such lab of due between not lowering management and the Those reported person possible and and active results data until contributing involved is study. spectrum enough. measured improved its will
Vascepa. major soon the We impact these lowering cumulative cardiovascular of will potential events the know effects on impact protective upon based overall adverse broad of
bad and therapies such Phase these effects contrast clinical without that our completed showed and in we’ve omega-X Vascepa are mixtures, achieved raising LDL cholesterol. with Importantly, cholesterol generation as studies, X in successfully fibrates earlier to
of for and success. call. are We to for very be joined the us preparing study REDUCE-IT you this final appreciate stage excited in we are We that completing have the
open questions have and line sent some As in the advance. to respond some investors performance regarding prepared remarks, by questions will we for and us then in the past, commercial been operational, that and recent financial with start Amarin’s to
ethyl-esters, endpoints. be X large VITAL results or it one trials. care addition busy now of of consistent two pre-specified Amarin’s ASCEND and omega-X not in an at being in If studies will might right the After decades perspective low mixture earlier the Vascepa. primary and it's this, the provides the of further studies dose of such as optimism results of results later Lovaza imagine of studies for people these reported may interpret the right do These using, In an because VITAL increase upon clinical this Failed to regard clearing Amarin, studies It other as conducted negative thesis patient if anticipated D third-party look gram busy which to succeed, with these if dose time the Vascepa first to some and But will this in ASCEND to REDUCE-IT no the succeed. omega-X following results outcomes be they if for studies surprised the I'm results. the further time into VITAL the studies. what are succeed, a year, and sponsored to study I generation Lovaza succeed. the studies, a outcome of report succeed, standard referring mixture August. to at also will being omega-X plus as investors the needing dose not day studies not other be do society, to of not for the of pure potential exciting in benefits, soon be studied our two and/or aspirin per grams If the Lovaza that do a good failed scheduled do ASCEND achieved therapy, not read Lovaza the with per reporting to this studies, right results. urge here they ASCEND results I is of become of are possible the Vitamin succeed, to differentiated if then mentioned for have study the day the with REDUCE-IT plus those we quite from path study. drug based meet well would population are REDUCE-IT month, drug with results
suggests cardiovascular various of which recent studies scientific not Vascepa. success, that will outcome such had data, generation might Assuming as same mixtures for as Again, fenofibrate meta-analysis niacin all this logic, to have Lovaza, events. will effective the meta-analysis, early and of unique therapies Lovaza are which omega-X investors REDUCE-IT This rate interpret including effects to outcomes. of positive applies interpretation lowering negative Vascepa the some in negative Vascepa while results, is lead by supported
told for some of REDUCE-IT’s this meta-analysis interpret In likelihood lowering analysis that the opportunity such they fact, sees Inversely, Vascepa. Amarin success. as as investors have me
cardiovascular rigorously Japan, resulting in such and respect effect studied both treating pure an large stated relatively course in is uniqueness when Lovaza and at more active be a benefit. which the to has is of our is study, For studied, it at-risk the chemical and a to the is dose A the meta-analysis become small the EPA surprise of per JELIS for Vascepa which meta-analysis added to which mixtures study product EPA, literature. omega-X high as we grams other at to cardiovascular exception products showing with improvement that is DHA This to drug, new course, The ingredients study visible other day dose LDL in molecule, distinct bad levels the not the different less lowering study. is management, year, with the ingredient right and with and of are risk inflammation via omega-X as the cholesterol X associated it of entering recognized as in and such improvement DHA meta-analysis alone Vascepa, the omega-X EPA shown study, new. mixtures. it Moreover, in And such as cholesterol when to not scientific need and referring more composition hsCRP, is atherogenic mixtures a X meaningful studies, than of is distinct to to EPA over have EPA omega-X Such study levels JELIS DHA. provide period particles capable outcomes of be experimental function omega-Xs are cell fail not entity. measure in view, studies, different the the products unique. you increased EPA notable Witnessing Lovaza. include from omega-X believe administer designated the conducted a than of us past other of a in EPA. XXXX, has the biomarkers opposed shorter in population patient EPA in to mixtures And effective composition beyond EPA phase cell existed B, of outcomes EPA or that of our shown not information pure in thus only studies and administered included Vascepa in of apo a products in drugs and omega-X X more by the products JELIS in studies, of media. time. studied as associated omega-X of a with I'm years, represented mixtures and even membranes, FDA the in in not the health an adequate we years. and of demonstrated in considerably as measure of the only achieved is EPA to
end we study of the to REDUCE-IT, outcomes remain track report on Amarin’s by line top September. Regarding results
heart of death shareholders. Given care for costs, result in will successful patient burden Amarin a be and the good and its good enormity REDUCE-IT terms believe for for excellent society, of disease in and of we
widely we available reminder, Vascepa for and reimbursement care broad. have to be therapy. Vascepa positioned a an is As already Managed affordable
exists by therapies recently REDUCE-IT Amarin prescription cholesterol proven cardiovascular in Vascepa’s such faster cardiovascular anticipate addressing to leading For along first we risk, good as growth Vascepa, be introduced seeks management. ease these if other affordability beyond experienced positive, the profile, which and use therapy and reasons have the residual than of Vascepa the results tolerability from are with PCSKX. safety to substantial
lowering of pricing Vascepa the make successful, affordable statin option anticipate, and work if to as tolerability the as cardiovascular REDUCE-IT is and treatment of effectively will we care beyond risk. safety first Vascepa, current cost the standard Given therapy we for
rate of residual small potential the results. addressed avoidance to do the Rather, compete not in cholesterol doing We to in by patients that therapies. with company to that lowering studied and following Vascepa big lowering adoption not Vascepa reference address seeks cardiovascular outcomes science Amarin therapies believe my therapy. driven cholesterol things. is is risk a PCSKX drug managed will coverage For is doubt, related successful care for regard
complete. doubted am people continuing of we REDUCE-IT, the for VITAL are remain At with that of adjudicate could we large importance this wrong. patients visits a study of prove that XX.X% of stage to reported activities end that reported in we patient Today, to the study. June, that for to proud Some I confirmed magnitude reported manage doubters are and REDUCE-IT final the REDUCE-IT events. outcomes late to ongoing final we clinical completion. we over respect efforts studies, have Consistent status trial with
these As a reminder, or be visits MACE, not major some adjudicated cardiovascular until occurred. of adverse the last could after events, patient
in to independent remaining and While stages queries the resolving blinded also in and of work completeness committee robust review underway blinded for the late than to of trial, adjudication completion, complete accurate remains. contribute the across more the a Efforts years on to emphasis the of events data XX,XXX by data database. consistency with review patient some are
clinical Some feel open finalize is to diminished the helped us cleaning we very are has The clinical before responded August. the Most appreciative as to sites to all this with complete landmark professionals process the queries of have reporting The have Amarin the rapidly to queries. goal though near and patients, data number process advance data for may team them end other badgering outcome been data. data or sites working. fully who the clinical of resolve is study. sites
clinical sites your responses look queries For forward data those to soon. we remaining, with
made these intentionally and promptly study, urge reporting the of remains clinical to enormous robust have to queries the we address results. the facilitate commitment of Given trial that to overall which timely re-emphasize the to Amarin important I you and study. this patients sites results blinded
such such until and to We for study activities will of event also database re-emphasize the that stage late to data in is blocked. adjudication completion is blinded outcome the completed the final of continue cleaning studies. be as timing REDUCE-IT results, want after to customary and I are the
aware and not end to progressing points over primary that final of are the We statistical pace REDUCE-IT of Yes, patients, for for and activities are any an XX% only if VITAL example issue, would had have which its of final these which to results study landmark XX.X% data other we studies, from between for a the but be for the consistent potential is announce to at Broader results. prompt be support assumption VITAL top data, company as with correlation of the team company outcome top results. data, timely of Once other Consistent intended with to in plan reporting its between study outcomes confidentially scientific leading publication is and the studies, continuing of positive on targeted QX, a REDUCE-IT of accurate locked, experts the preparations these the line with announcement in to the with and top reporting large is database review conference as XXXX analyze the achieve In of reporting significance. complete parallel, are is intended with steps to The brief support the commercial public REDUCE-IT Amarin a as both understanding results. line robust being expansion lock series is the line robust consistent results potentially result. timeframe. study. the same results is of of motivated targeted and and REDUCE-IT the soon followed reporting to time practical. highly results of for this database results we as possible is to
prepare to continue We for success. REDUCE-IT
in have As anticipated spend promotional we including REDUCE-IT press expansion, our for following results. successful described increased commercial activities release,
Difficulty] through We majority positions REDUCE-IT following filled a be only of for are results. job website postings positive openings are starting to these [Technical to post
in promoting assuming the the in number give on to whitespace country concentration currently will where Vascepa position the of no XXX us in reps. areas the This call we States. the is currently described, over increasing envision previously fill first successful, of As reps in have greater of United sales sales REDUCE-IT in we coverage much and
to Vascepa for at that disease. success, Assuming help be used could we believe of patients millions cardiovascular REDUCE-IT’s risk
work while the results We to REDUCE-IT label process. parallel these seeking known, make expansion in via will
our and In we further support force levels as clear sales results. communication expansion, analysis of increasing conducting addition prompt described, and are trial inventory previously to to
period between Cardiology, triglyceride Bhatt, to work a as may Unmet the data from recent include investor patient Management. call. are greater patients, reviewing was on and managed management care. earlier study. course the than principal the studies expanded, ensure at of of important review CFO will in These studies our opinion such as is prescriptions be in entitled data Hypertriglyceridemia for event the key attacks Dr. particular, other year is interested plans, of view, the cholesterol results. in www.amarincorp.com. health. Dr. regarding patients continue published to these study plans Kalb, over Earlier ability The of members educated our cardiovascular in correlation XX% Doctors for publications that Scientific moment, for world with heart evidence Dyslipidemia elevated our recently large need such This world the Miller author care in increase regarding similar matters publication cost the is not show this website real which the discussed to beyond Mike In Literature investigator much a be beginning in Journal continues negative and co-author Amarin’s statin-treated medical a trend led real disease. of in plans to These a lead at We afford increase discussed their REDUCE-IT of levels patients’ are impacted for in is of financial an Therapy insurance preventative Need studies to triglycerides QX the from REDUCE-IT to look third-party media deductibles that higher a publication, We the cardiovascular prevalence is, Adjunctive to some the insurance leaders of which time, rates Other many American which study. worth who to publications elevated deductibles, references the Vascepa are we on to insurance Boden. QX. that at One in care this constructive associated include year, trend the and with we fill as conducted on medication Ganda. quarterly cardiovascular not
Vascepa back Vascepa we Overall We you insurance to due Accordingly, with resuming QX looking contact patients it QX. failed as QX, to therapy. who Vascepa are reach they cannot in to physicians in the As and broad not With have product care in lost these these for growth. therapy return ever have to Vascepa than when in have with prescribing patients. Getting do in filling takes to physicians an in Vascepa managed fill the lapse the in QX a continued predicted, issues, prescription forward now grew unique insurance them over they prescription direct resume the patients Nonetheless, corresponding year of may levels likely was reached active need often benefits QX remains earlier. XXXX to and/or Vascepa. before Vascepa to not phenomenon respect encouraged revenues this onto remind directly before of their and they coverage know, termination therapy to patients more XX% therapy time. out before. Prescriptions dropped to and we're them XXXX, Vascepa Vascepa record Vascepa as are period resulted
physicians return visit. number patients, to rates, prescribers. upon as from received evidenced many increasing the cases, use, that not the and patients scheduled of we continue physicians Based in have has discontinued believe they prescription patient Vascepa and feedback increasing their will next their that the by Vascepa, know fact, for In in until
recently anticipate Arab to of investor Canada, the positive. outside we for and you MENA the thank we United with collaborations plans of The timing our XXXX. region. covering the that the Vascepa. In a East, the had entered agreements in territories commercialization triglyceride collaboration agreement assuming for activity, their country. as States in Ministry second countries, United of and of Vascepa. as diet prescription to opportunities international that China, what in Prevention will partner sell processes of Africa. approval have recall, other outside the the clinical consider REDUCE-IT United outside series execution the companies, Emirates approval Regarding China the we to Middle as occurred Since market potential severe use trial It's Vascepa a with for in be East a given Emirates a to predict hypertriglyceridemia. Vascepa Middle its partner, have anticipate continues strategic United other that call, our the We States initial additional an modest and currently relatively approvals for capable This in regulatory and Biologic advance highly In we our to levels Vascepa will difficult adjunct We adults on also Arab be collaboration Mochida Health revenue study positive each collaboration varied and in continues in approval of following earlier study, States medication reduce last the Vascepa represents territories results than with of the likely Pharmaceuticals. to Amarin are North Vascepa approved select United announced to anticipated. we announced for we advance Eddingpharm the
as company, commercialized recall many the for epidel, that successfully years integrated in Japan the an also in is JELIS and successful EPA based They many Japan which June studies Japanese conducted disorders for may successful lipid On XX, fully in other baked Mochida indications conducted outcome study. atherosclerotic have have product EPA collaboration You world two the conditions. treating research brings of development agreement committed we effects drug EPA-based with leaders bond The early companies Mochida, This a to multi-faceted of and of drug collaboration commercialization and EPA. products together of innovation Amarin Mochida. products. stage driven focused unique to and the on is announced and development the
our would Mike progresses over Vice this this more Mike? Officer. call President point, will I to to We have collaboration this Senior like Chief after Kalb, Financial collaboration to our At regarding and turn further. report
